The causes of encephalopathy in the posttransplant setting are diverse and include medication toxicity (e.g., posterior reversible encephalopathy syndrome), infections (e.g., human herpes virus type 6 [HHV-6]), and neoplastic disease (posttransplant lymphoproliferative disorder). Autoimmune etiologies are not well recognized in this setting, although a few cases are described.1,–,5 Herein, we report 3 patients with posttransplant autoimmune encephalitis (AE).
Methods
Standard protocol approvals, registrations, and patient consents
All 3 patients consented to the use of their medical records for research purposes.
Case reports
We retrospectively identified patients by searching the Mayo Clinic (Rochester, MN) electronic medical record and Neuroimmunology Laboratory database from January 1, 2005, to January 1, 2018. Three patients met the inclusion criteria: (1) definite autoimmune encephalitis by 2016 criteria6 and (2) neurologic onset after solid-organ or hematopoietic stem cell transplantation (HCT). Neural autoantibody (Ab) testing occurred at the Mayo Clinic Neuroimmunology Laboratory, as previously described.7
Case 1
A 68-year-old Caucasian woman presented with psychosis, orofacial dyskinesias, and memory loss 10 years after a heart transplant for dilated cardiomyopathy. Maintenance immunosuppression at that time included tacrolimus and mycophenolate mofetil. She was initially diagnosed with psychotic depression. MRI revealed subtle right mesial temporal T2-hyperintensity (figure, A). CSF revealed elevations in the white blood cell count (62/µL; normal, <5) and protein level (59 mg/dL; normal, <45 mg/dL). CSF N-methyl-D-aspartate (NMDA) receptor (R) ab (titer 2 [normal, <2]; positive cell-based assay [CBA]) and Epstein-Barr Virus (EBV) PCR were positive, but HHV-6 PCR was negative. PET-CT body was normal. Additional immunosuppressive treatment with IV methylprednisolone (IVMP) × 12 weeks and rituximab (1 g IV × 2 doses) resulted in resolution of psychosis and memory improvement (34/38–38/38 on Kokmen Short Test of Mental Status [STMS]). She was maintained on cyclosporine and mycophenolate. The modified Rankin Scale (mRS) score was 0 at 24 months from onset.
(A) Right mesial temporal T2-hyperintensity (arrow) on coronal Fluid-attenuated inversion recovery (FLAIR) in a patient with posttransplant anti-NMDA receptor encephalitis. (B) Bilateral (right more than left) mesial temporal T2-hyperintensity (arrows) in a patient with posttransplant anti-AMPA receptor encephalitis. (C) Concurrent midbrain enhancement (arrow) and bilateral optic nerve enhancement (arrowheads) in patient with posttransplant myelin oligodendrocyte glycoprotein antibody disease.
Case 2
A 61-year-old Caucasian man had subacute memory loss and disorientation 1 month after liver transplant for sclerosing cholangitis. He had received basiliximab and had commenced tacrolimus and mycophenolate mofetil for maintenance immunosuppression. MRI revealed bilateral mesial-temporal T2-signal abnormality (figure, B). The CSF white cell count and protein level were normal, and HHV-6 PCR was negative. Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid Receptor (AMPAR) ab was detected in serum (titer = 30,720; CBA positive) and CSF (titer = 32; CBA positive). CT body was essentially normal. Additional immunosuppression with IVMP (1 g/d for 5 days and then weekly), plasmapheresis (x5), IVIg (0.4 g/kg weekly), rituximab (1 g intravenously × 2 doses), and later oral prednisone (40 mg/d) and a switch from tacrolimus to cyclosporine resulted in improved cognition (26/38–33/38 on Kokmen STMS). Twelve months after onset, his mRS score was 3.
Case 3
A 54-year-old Caucasian woman presented with subacute encephalopathy and bilateral vision loss (left > right) 38 months after HCT for multiple myeloma. She was not taking maintenance immunosuppression but had previously received cyclophosphamide, bortezomib, dexamethasone, and melphalan. MRI showed enhancement of the brainstem, thalamus, and optic nerves (figure, C) consistent with acute disseminated encephalomyelitis (ADEM). CSF revealed an elevated white blood cell count (568/µL; 79% neutrophils) and protein level (117 mg/dL). Serum myelin oligodendrocyte glycoprotein (MOG) ab was positive by fluorescent-activated cell-sorting live CBA (IgG-binding-index 49.7; normal, <2.5). PET-CT body was normal. Five days of IVMP (1 g/d) resolved her encephalopathy, but left eye visual acuity remained 20/400 and the mRS score was 1 at last follow-up, 26 months after onset.
Discussion
We show that AE can occur posttransplant and highlight the potential benefit of additional immunosuppression, particularly antibody/B-cell depleting therapy. Our identification of 3 patients over a 13-year timeframe at our facility and the few previous reported cases suggests that posttransplant AE is rare, but could also reflect AE diagnoses being overlooked in patients receiving immunosuppression.
Each included patient had a neural autoantibody of pathogenic potential with a compatible clinical syndrome (NMDAR: psychosis and orofacial dyskinesia; AMPAR: limbic encephalitis; MOG: ADEM) and improved with additional immunosuppression supporting AE over competing diagnoses. Three case reports of posttransplant anti-NMDAR encephalitis are described. One case occurred 16 months after kidney transplantation for radiation nephropathy preceded by HCT for non-Hodgkin lymphoma5; the 2 other cases were after renal transplant for reflux nephropathy and pyelonephritis, respectively2,3; all developed AE while taking immunosuppressants (mycophenolate, 3; prednisone, 2; tacrolimus, 1). Similar to our anti-NMDAR encephalitis patient, 2 cases had concurrent EBV infection detected in CSF potentially suggesting a post-infectious AE similar to post-HSV encephalitis or facilitation by blood-brain barrier breakdown with EBV infection or reactivation. Similar to our case of ADEM with MOG Ab, ADEM cases posttransplant are described, but most reports preceded MOG Ab availability.1 Leucine-rich glioma-inactivated 1 (LGI1) ab encephalitis in a child 15 months after HCT for aplastic anemia is also reported.4 HHV-6 reactivation is associated with limbic encephalitis posttransplant (particularly HCT), but our patients with limbic encephalitis tested negative. Our report suggests that imbalance between B- and T-cell depletion can provoke autoimmunity, similar to how it occurs with congenital (e.g., Di-George syndrome) and iatrogenic (e.g., alemtuzumab) immunodeficiency.
Author contributions
D. Cohen: drafting of the manuscript, data acquisition, and analysis and interpretation. A.S. Lopez-Chiriboga, S. Pittock, A. Gadoth, A. Zekeridou, B.A. Boilson, W. Hogan, J.J. Poterucha, K.M. Wilton, and Y. Lin: analysis and interpretation and critical revision of the manuscript. E. Flanagan: study concept and design, analysis and interpretation of data, critical revision of the manuscript, and study supervision.
Study funding
No targeted funding reported.
Disclosure
D. Cohen reports no disclosures. S. Pittock provided consultation to Alexion Pharmaceuticals and Medimmune but has received no personal fees or personal compensation for these consulting activities. All compensation for consulting activities is paid directly to Mayo Clinic. S. Pittock has received research funding from Grifols, Medimmune, Alexion, and AEA (Autoimmune Encephalitis Associations). A. Gadoth reports no disclosures. A. Zekeridou reports no disclosures. B.A. Boilson reports no disclosures. W. Hogan received research support from Osiris Therapeutics. J.J. Poterucha served on the editorial board of the American Journal of Gastroenterology. K.M. Wilton received research support from the National Institutes of General Medical Sciences. Y. Lin reports no disclosures. E. Flanagan received research support from Medimmune. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NN.
Footnotes
Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NN.
The Article Processing Charge was funded by the authors.
- Received June 7, 2018.
- Accepted in final form June 22, 2018.
- Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Topics Discussed
Alert Me
Recommended articles
MOG antibody–positive, benign, unilateral, cerebral cortical encephalitis with epilepsy
Clinical and imaging features of children with autoimmune encephalitis and MOG antibodies
Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis
Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton